The Biology Behind the Investment
Cellular senescence is a state that cells enter when they sustain damage that triggers permanent cell cycle arrest. Senescent cells do not die in the way that normal damaged cells do through programmed cell death. Instead they persist in tissues in a metabolically active state, secreting a complex mixture of inflammatory cytokines, proteases, and growth factors that collectively constitute the senescence-associated secretory phenotype. The SASP was initially understood as a tissue repair signalling mechanism, and it serves that function acutely. The problem emerges when senescent cells accumulate in tissues over decades, as they do during normal ageing and more rapidly in response to certain stresses including cancer therapy, radiation, and obesity. The chronic low-grade inflammation generated by accumulated senescent cells is increasingly understood as a driver of the age-related diseases that determine the quality and duration of human life. Osteoarthritis, cardiovascular disease, type 2 diabetes, pulmonary fibrosis, neurodegeneration, and frailty all have evidence linking their pathophysiology to senescent cell accumulation and the chronic inflammatory environment that SASP creates.
Senolytics are drugs that selectively eliminate senescent cells by exploiting the survival mechanisms that senescent cells depend on to resist apoptosis despite the cellular damage they have accumulated. The hypothesis that clearing senescent cells would reduce the pathological consequences of their accumulation was first demonstrated in transgenic mouse models by the Mayo Clinic research group of Darren Baker and Jan van Deursen, published in Nature in 2011. The mice whose senescent cells could be selectively cleared lived longer and showed delayed onset of age-related diseases compared with control animals. The subsequent development of pharmacological senolytics, drugs that achieve selective senescent cell elimination without genetic manipulation, has been the translational challenge that the commercial senolytic market is built around. The combination of dasatinib and quercetin, identified by Mayo Clinic researchers as the first pharmacological senolytic combination, and navitoclax, a BCL-2 family inhibitor that exploits senescent cells' dependence on BCL-2 family proteins for survival, are the drug candidates that have moved most rapidly into clinical development.
The Clinical Development Landscape
Unity Biotechnology was the first company founded specifically to develop senolytics as pharmaceutical products, and its clinical journey has provided both the promise and the sobering commercial lessons of the senolytic field. Its UBX0101, a navitoclax-derived BCL-2 inhibitor delivered intra-articularly for knee osteoarthritis, failed to meet its primary endpoint in a Phase 2 clinical trial in 2020. The failure was attributed to the relatively small effect size of local senolytic treatment in a disease whose pathology extends beyond the joint itself, and it illustrated the challenge of designing clinical trials for senolytic interventions whose mechanism of action is fundamentally different from conventional symptom-targeting drugs. Unity subsequently pivoted toward eye diseases including macular degeneration and diabetic macular edema, where senescent cell accumulation in the retinal pigment epithelium is mechanistically implicated and where local drug delivery can achieve meaningful senolytic effect in a well-defined tissue target.
The clinical development programmes for senolytics in indications beyond osteoarthritis have expanded substantially since 2020 as the biological understanding of senescence has deepened and as the academic and commercial research community has developed more refined understanding of which patient populations, which tissues, and which methods of senolytic delivery are most likely to produce measurable clinical benefit. Pulmonary fibrosis, whose natural history of progressive lung scarring and associated senescent cell accumulation provides both a clear biological rationale and a well-defined clinical endpoint, is the indication where the dasatinib-quercetin combination has shown the most encouraging clinical signal. Intermittent dosing protocols, which take advantage of the therapeutic window between senolytic efficacy in senescent cells and toxicity in non-senescent cells, are a clinical innovation whose development reflects the increasing sophistication of senolytic clinical design relative to the early trials that applied conventional continuous dosing assumptions to a fundamentally different pharmacological mechanism.
The Pharmaceutical Industry's Increasing Engagement
The engagement of large pharmaceutical companies in senolytic and senomorphic drug development has increased substantially as the preclinical and early clinical evidence has accumulated. AstraZeneca, Novartis, and several other major pharmaceutical companies have either partnered with or acquired senolytic-focused companies, or have initiated internal programmes whose investment reflects a genuine assessment that senescence biology represents a druggable pathway for age-related disease modification. The commercial case for pharmaceutical investment in senolytics rests on the potential to develop disease-modifying treatments for age-related conditions whose current standard of care is symptomatic management rather than biological intervention. A senolytic therapy that demonstrably slows the progression of osteoarthritis, pulmonary fibrosis, or diabetic eye disease by clearing the senescent cells that drive their pathology would address markets whose commercial scale is measured in tens of billions of dollars and whose current therapies provide incomplete and unsatisfying clinical solutions.
Top 10 Companies in Senolytic and Longevity Therapeutics Globally
- Unity Biotechnology: First commercial senolytic company whose UBX1325 for diabetic macular edema and age-related macular degeneration is in Phase 2 clinical development; its pivot from joint disease to eye disease reflects the lesson from its UBX0101 Phase 2 failure that local delivery to well-defined senescent cell populations provides the best near-term clinical development pathway.
- Oisin Biotechnologies: Developing a lipid nanoparticle-delivered gene therapy that selectively kills cells expressing the p16 senescence marker; its approach avoids the off-target effects that small molecule senolytics face by restricting cytotoxic expression to cells with the molecular signature of senescence rather than exploiting a survival pathway that non-senescent cells also express.
- Cleara Biotech: Dutch senolytic company developing FOXo4-DRI peptide senolytics that restore p53-mediated apoptosis in senescent cells; its peptide approach and its academic origins in the Peter de Keizer group at Utrecht University provide the mechanistic specificity that distinguishes it from the broader cytotoxic senolytics in commercial development.
- Mayo Clinic (Baker/Kirkland Labs): The academic origin of both the genetic and pharmacological senolytic proof of concept; its ongoing clinical trials of dasatinib-quercetin in multiple age-related conditions are generating the human clinical evidence that commercial senolytic programmes use to inform their development strategies.
- Novartis: Major pharmaceutical company with internal senescence biology research and its acquisition of The Medicines Company assets that include senescence-related cardiovascular programmes; its investment represents the large pharma validation that the senolytic field has been seeking since Unity's Phase 2 setback.
- Recursion Pharmaceuticals: AI drug discovery company whose senescence biology platform is identifying novel senolytic drug candidates through phenotypic screening at scale; its computational approach to senolytic discovery accelerates the identification of drug candidates with better selectivity profiles than the first-generation senolytics whose broad mechanism of action creates toxicity challenges.
- Calico (Google/Alphabet): Alphabet's longevity research company with significant investment in the biology of ageing including senescence; its research infrastructure and its long-term investment horizon create the conditions for fundamental longevity biology research that is less accessible to companies operating under conventional pharmaceutical development timelines.
- Altos Labs: Biological reprogramming research company funded with over three billion dollars from Jeff Bezos and others; its cellular rejuvenation research addresses the deeper ageing biology that senolytic clearance alone may not resolve, making it the most ambitious commercial investment in fundamental longevity science.
- NewLimit: Brian Armstrong-backed epigenetic reprogramming company developing cellular rejuvenation approaches for age-related disease; its focus on the epigenetic clock mechanisms that determine biological rather than chronological age represents the mechanistic sophistication that the longevity therapeutics field is developing beyond first-generation senolytic approaches.
- CohBar: Mitochondria-based therapeutics company targeting the mitochondrial dysfunction that accompanies and contributes to cellular senescence; its CB5945 programme for NASH and its pipeline addressing age-related metabolic disease represent the mitochondrial intervention layer of longevity therapeutics that senolytic approaches alone do not address.